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Abstract
Background: Cancer of unknown primary site is still a demanding condition as it is per definition metastatic, with
heterogeneous biological behavior, and it is often resistant to therapy. Cancer of unknown primary site accounts for
approximately 1 to 5 % of all cancers, but is currently among the top six causes of cancer deaths in Western countries.
To correctly identify the biological origin of the tumor, a large spectrum of differential diagnoses must be considered
and scrutinized. At progression, re-biopsy might be necessary to reveal the true origin of the tumor or actionable
targets.
Case presentation: A 62-year-old Norwegian woman, with a fast growing lump in her left groin, was primarily
diagnosed as having undifferentiated carcinoma that was BRAF V600 positive. There was complete response
with paclitaxel-carboplatin and she was recurrence-free for 18 months. She had recurrence in both lungs and
subcutaneously in her left groin and thigh; a re-biopsy revealed transformation to a malignant melanoma. She
was resistant to BRAF inhibitors, then treated with ipilimumab and is currently a long-term survivor of 4 years
and 4 months since the first diagnosis, with no clinical or radiological evidence of recurrence.
Conclusions: A biopsy from patients with metastasis of unknown primary should be analyzed thoroughly to
identify organ of origin, molecular make-up, and possible molecular targets. Re-biopsy of cancer of unknown
primary site at progression can reveal the true cellular origin of the tumor as well as provide novel
therapeutic opportunities, including immunotherapy.
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Background
Cancer of unknown primary site (CUP) accounts for ap-
proximately 1 to 5 % of all cancers but has a dismal
prognosis of approximately 10 to 20 % 1-year survival
and in Australia is the sixth cause of cancer death [1–4].
Depending on the patient series, up to 40 % of patients
with CUP are diagnosed as having metastasis in their
lymph nodes, while the remaining patients present with
metastasis in their internal organs [5, 6]. In a large series
of CUP in various anatomical regions, patients with an
affected lymph node showed a wide survival span;
patients presenting with affected inguinal lymph nodes
had a median survival of 18 months and patients
affected intra-abdominally had a median survival of only
4 months [7]. Thus CUP is a very heterogenous entity,
where histopathological examination, immunohistochemi-
cal profiling, and molecular profiling of the tumor are
necessary to improve treatment and survival of patients
with these tumors.
The complexity and unusual features of the history of
this 62-year-old woman with a fast-growing mass in her
left inguinal area, has taught us a lesson that may be im-
portant to share with oncologists treating this patient
population.
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Case presentation
A 62-year-old woman of Norwegian ethnicity, previously
healthy, presented in September 2012 with a large fast-
growing nodal mass in her left groin; a computed tomog-
raphy (CT) scan showed a 62 mm tumor infiltrating the
subcutis. A clinical examination did not reveal any other
pathological glands or any skin lesions. An magnetic
resonance imaging (MRI) of her pelvis showed a solitary
tumor, and subsequent CT of her thorax and abdomen,
mammography, and endoscopy could not reveal or indi-
cate the primary location of the tumor; in addition, the
tumor markers we use in our screening were all within
normal range: carcinoembryonic antigen (CEA), CA125,
CA15-3, CA19-9, neuron-specific enolase (NSE), and
chromogranin A (CgA). In November 2012 the tumor was
still regarded as operable and surgery was performed. On
macroscopic examination, the tumor was a 57 mm solid
tumor. Histopathological examination revealed a tumor
composed of malignant epithelioid cells, which on immu-
nohistochemical examination stained positive for cytoker-
atin (CK) AE1/AE3 (diffuse), CK7 (focally), CD10,
vimentin, and epithelial membrane antigen (EMA; scat-
tered tumor cells). S100 was positive in scattered cells
with dendritic features and possibly in a few scattered
tumor cells. Nearly 100 % of the tumor cells were positive
for Ki67/MIB1. The cells were negative for BerEP4, CK20,
CK5/6, p63, thyroid transcription factor 1 (TTF1), synap-
tophysin, chromogranin, estrogen and progesterone
receptors, human melanoma black 45 (HMB45), melan A,
leukocyte common antigen (LCA), desmin, myogenin,
smooth muscle actin (SMA), and CD30 (Fig. 1). We
screened for actionable targets and molecular genetic
analysis was negative for KRAS and synovial sarcoma
marker, translocation t(X;18), but revealed BRAF
V600E mutation. In the final pathology report, the
tumor was classified as a metastasis from an undiffer-
entiated carcinoma.
Our patient had postoperative complications with in-
fection and lymphatic leakage, subsequent CT scanning
and positron emission tomography (PET)-CT showed
masses to be growing deeper in her pelvis, which could
not be removed (Fig. 2).
We decided to give paclitaxel with carboplatin (AUC5)
every 3 weeks, which is a standard treatment for CUP
and after four courses the masses went into complete re-
mission. Consolidation radiotherapy was performed
April to May 2013, 2×(25 to 50) Gy. Our patient was in
very good general condition during all the treatment
period: World Health Organization (WHO) performance
status (PS) grade 0. The remission lasted for 18 months
to July 2014, when multiple, fast-growing subcutaneous
nodules evolved within and near the surgical wound and
radiation field and distally on her left thigh. Moreover,
multiple small metastases were seen in both her lungs.
One subcutaneous nodule was extirpated for histopatho-
logical analysis, which revealed a tumor with a cellular
morphology and cellular growth pattern similar to the
tumor resected 18 months earlier. The tumor cells were,
as previously, negative for BerEP4, CK20, CK5/6, P63,
HMB45 and melan A, but surprisingly CK AE1/AE3 was
now negative and S100 strongly positive in all tumor
cells (Fig. 3). The tumor cells were closely studied, both
Fig. 1 Tumor resected in 2012. The resection revealed malignant epithelioid cells with pale eosinophilic cytoplasm and pleomorphic nuclei with
vesicular chromatin; hematoxylin, eosin and saffron staining (a). The resection revealed a positive reaction for cytokeratin AE1/AE3 (b). Scattered
cells stained positive for S100 (c) and CD68 (d), representing tumor-associated macrophages, but tumor cells were S100 negative
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initially when the first report was made and on reevalua-
tion, and conspicuous pigment was not detected.
The BRAF V600E mutation persisted, strongly indicat-
ing that the tumor was of the same origin but probably
another clone, or a transformation from the primary
tumor after chemoradiation with an unusual or aberrant
expression profile for a melanoma.
Due to the previous good results with chemotherapy, one
course of paclitaxel and carboplatin was tried. However, the
nodules grew more aggressively, and chemotherapy was
discontinued in favor of a BRAF inhibitor, dabrafenib, that
showed a brief response of 2 months, and subsequently
vemurafenib was administered resulting in progressive dis-
ease. Combined treatment with a mitogen-activated protein
kinase (MEK) inhibitor was not introduced in Norway at
that time point. In the meantime, ipilimumab was approved
for use in melanomas in Norway and in December 2014
she was offered this treatment. After four cycles of ipilimu-
mab there was a complete response in her skin and her
lungs, with no reported side effects (Fig. 4).
Today, 4 years and 4 months after primary diagnosis of
aggressive CUP and 2 years and 6 months after metastatic
melanoma was diagnosed in the re-biopsy, she is radio-
logically and clinically cancer-free (Fig. 5).
Discussion
Diagnosis is often difficult in CUP. On microscopic
examination of the first resected left groin tumor that
was a lymph node metastasis, malignant melanoma was
excluded due to the immune profile with CK AE1/AE3
Fig. 2 The patient had postoperative complications with infection
and lymphatic leakage. Subsequent positron emission tomography-
computed tomography (a) showed masses to be growing deeper in
the pelvis, which could not be removed surgically (white arrow).
Computed tomography scanning (b) showed complete remission
after four courses of paclitaxel and carboplatin (white arrow)
Fig. 3 Several subcutaneous recurrent tumors developed after 18 months. A biopsy showed cells with a growth pattern, cellular features, and
nuclear features similar to the tumor resected in 2012 seen by hematoxylin, eosin and saffron staining (a), but a change to negative staining for
cytokeratin AE1/AE3 (b) and now positive staining for S100 (c)
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positivity and negative reaction for three melanoma
markers. Due to this finding we re-stained the primary
biopsy with S100, as well as HMB45 and melan A. All
three markers were negative. Of interest, the few scat-
tered S100 positive cells with dendritic features were
also positive for CD68, and thus believed to represent
tumor-associated macrophages.
Malignant melanomas, especially metastases, are known
for aberrant immunohistochemical features in some cases.
Expression of various non-melanoma markers, including
intermediate filaments and loss of classical melanoma
markers is not unusual [8, 9] and awareness of the possi-
bility of unusual immunophenotypes is crucial for the
right diagnosis. BRAF mutations are most commonly
associated with malignant melanomas, colorectal adeno-
carcinomas, and papillary thyroid carcinoma and could
therefore be helpful in identifying the origin of the tumor
[10, 11]. Neither the clinical picture nor the histopatho-
logical examination supported the two last diagnoses.
Moreover, the metastasis localized in the surgical field
where the primary lymph nodes had infiltrated the skin,
also indicated that this was the same tumor. In hindsight,
the simultaneous finding of a BRAF mutation, combined
with the localization and morphology of the tumor, should
have aroused our suspicion of an aberrant malignant
melanoma. Thus we conclude that in our case, the undif-
ferentiated CUP probably was transformed to, or at least
acquired the molecular characteristics of, a melanoma at
recurrence, and was successfully treated with immune
checkpoint therapy.
Metastatic melanoma was treated with chemotherapy
in general until recently when the use of BRAF, MEK,
CTL-4, and PD-1 inhibitors showed increased survival
for patients, even beyond 5 years in a subset of patients
[12, 13]. A predictive marker for BRAF inhibitors in
melanoma is the BRAF V600E mutation, where positive
tumors have a high response rate with increased
progression-free survival for patients and when combined
with a MEK inhibitor there is increased overall survival
[14, 15]. Positive predictive markers for PD-1 inhibition in
melanoma appear to be positive PD-L1 expression in a
tumor [16] and low expression is predictive for combined
PD-L1/CTL-4 inhibition. Moreover, checkpoint inhibitors
seem to be very effective in several types of tumors with a
Fig. 4 At recurrence the patient had multiple small metastases in both lungs (red arrows) and multiple subcutaneous nodules in her left groin
and thigh (white arrows). There was no effect of chemotherapy and only 2 months’ effect of dabrafenib. Panels a and b show before treatment
with ipilimumab and c and d after two cycles where a significant remission was seen. After four cycles she was completely tumor free, and still is
with virtually no side effects
Fig. 5 Timeline of the key events
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high mutational burden as well as in tumors with micro-
satellite instability and/or mismatch repair deficiency [17].
In our patient, neither PD-L1 expression nor microsatel-
lite status was evaluated. However, in the future, given the
possible therapeutic implications, this may well become
part of a future biomarker panel in both CUP and
melanoma.
From the patient’s perspective, the decision to re-biopsy
this recurrent CUP turned out to become a life-saving
procedure that changed her future.
Conclusions
Currently, with the advent of targeted treatment and
immunotherapy, identifying molecular subtypes may be of
benefit for several cancer types. Immunotherapy, by ipili-
mumab, a fourth-line treatment, induced a complete and
durable response after recurrence and progression on
chemoradiotherapy and two BRAF inhibitors. Moreover
this patient had clinical benefit with paclitaxel-carboplatin
on what was perceived as an undifferentiated carcinoma,
which became resistant when transformed to a S100-
positive melanoma.
In conclusion, molecular screening in the primary
biopsy and re-biopsy of the recurrence may be of clinical
value in CUP, where evaluations with a broad spectrum
of immunohistochemical and molecular analyses are
necessary.
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